Compare STRS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | ACIU |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.5M | 213.3M |
| IPO Year | 1994 | 2015 |
| Metric | STRS | ACIU |
|---|---|---|
| Price | $29.90 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 14.6K | ★ 240.0K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 512.50 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $29,914,000.00 | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $20.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.28 | $1.45 |
| 52 Week High | $32.93 | $4.00 |
| Indicator | STRS | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 50.44 |
| Support Level | $28.22 | $2.56 |
| Resistance Level | $31.30 | $3.46 |
| Average True Range (ATR) | 1.00 | 0.20 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 10.43 | 51.60 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.